Literature DB >> 33670518

Small in Size, but Large in Action: microRNAs as Potential Modulators of PTEN in Breast and Lung Cancers.

Asal Jalal Abadi1, Ali Zarrabi2, Mohammad Hossein Gholami3, Sepideh Mirzaei4, Farid Hashemi5, Amirhossein Zabolian6, Maliheh Entezari1, Kiavash Hushmandi7, Milad Ashrafizadeh2,8, Haroon Khan9, Alan Prem Kumar10,11.   

Abstract

MicroRNAs (miRNAs) are well-known regulators of biological mechanisms with a small size of 19-24 nucleotides and a single-stranded structure. miRNA dysregulation occurs in cancer progression. miRNAs can function as tumor-suppressing or tumor-promoting factors in cancer via regulating molecular pathways. Breast and lung cancers are two malignant thoracic tumors in which the abnormal expression of miRNAs plays a significant role in their development. Phosphatase and tensin homolog (PTEN) is a tumor-suppressor factor that is capable of suppressing the growth, viability, and metastasis of cancer cells via downregulating phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling. PTEN downregulation occurs in lung and breast cancers to promote PI3K/Akt expression, leading to uncontrolled proliferation, metastasis, and their resistance to chemotherapy and radiotherapy. miRNAs as upstream mediators of PTEN can dually induce/inhibit PTEN signaling in affecting the malignant behavior of lung and breast cancer cells. Furthermore, long non-coding RNAs and circular RNAs can regulate the miRNA/PTEN axis in lung and breast cancer cells. It seems that anti-tumor compounds such as baicalein, propofol, and curcumin can induce PTEN upregulation by affecting miRNAs in suppressing breast and lung cancer progression. These topics are discussed in the current review with a focus on molecular pathways.

Entities:  

Keywords:  PTEN; breast cancer; cancer therapy; circular RNA; long non-coding RNA; lung cancer; microRNA

Mesh:

Substances:

Year:  2021        PMID: 33670518      PMCID: PMC7922700          DOI: 10.3390/biom11020304

Source DB:  PubMed          Journal:  Biomolecules        ISSN: 2218-273X


  323 in total

Review 1.  Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer.

Authors:  Muthu K Shanmugam; Sudha Warrier; Alan P Kumar; Gautam Sethi; Frank Arfuso
Journal:  Curr Vasc Pharmacol       Date:  2017       Impact factor: 2.719

2.  miR-10b expression in breast cancer stem cells supports self-renewal through negative PTEN regulation and sustained AKT activation.

Authors:  Ivan Bahena-Ocampo; Magali Espinosa; Gisela Ceballos-Cancino; Floria Lizarraga; Denise Campos-Arroyo; Angela Schwarz; Vilma Maldonado; Jorge Melendez-Zajgla; Patricia Garcia‐Lopez
Journal:  EMBO Rep       Date:  2016-04-09       Impact factor: 8.807

Review 3.  Dual role of autophagy in hallmarks of cancer.

Authors:  Shikha Satendra Singh; Somya Vats; Amelia Yi-Qian Chia; Tuan Zea Tan; Shuo Deng; Mei Shan Ong; Frank Arfuso; Celestial T Yap; Boon Cher Goh; Gautam Sethi; Ruby Yun-Ju Huang; Han Ming Shen; Ravi Manjithaya; Alan Prem Kumar
Journal:  Oncogene       Date:  2017-12-19       Impact factor: 9.867

Review 4.  Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives.

Authors:  Pei Shi Ong; Louis Z Wang; Xiaoyun Dai; Sheng Hsuan Tseng; Shang Jun Loo; Gautam Sethi
Journal:  Front Pharmacol       Date:  2016-10-25       Impact factor: 5.810

5.  Dual roles of miR-374a by modulated c-Jun respectively targets CCND1-inducing PI3K/AKT signal and PTEN-suppressing Wnt/β-catenin signaling in non-small-cell lung cancer.

Authors:  Mengyang Zhao; Ping Xu; Zhen Liu; Yan Zhen; Yiyu Chen; Yiyi Liu; Qiaofen Fu; Xiaojie Deng; Zixi Liang; Yonghao Li; Xian Lin; Weiyi Fang
Journal:  Cell Death Dis       Date:  2018-01-23       Impact factor: 8.469

6.  A novel small-molecule inhibitor of trefoil factor 3 (TFF3) potentiates MEK1/2 inhibition in lung adenocarcinoma.

Authors:  Mengyi Zhang; Baocheng Wang; Qing-Yun Chong; Vijay Pandey; Zhirong Guo; Ru-Mei Chen; Lingzhi Wang; Yanxin Wang; Lan Ma; Alan P Kumar; Tao Zhu; Zheng-Sheng Wu; Zhinan Yin; Boon-Cher Goh; Peter E Lobie
Journal:  Oncogenesis       Date:  2019-11-04       Impact factor: 7.485

7.  Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis.

Authors:  Hao Liu; Ying Song; Huishi Qiu; Yanzhen Liu; Kai Luo; Yanmei Yi; Guanmin Jiang; Minying Lu; Zhijie Zhang; Jiang Yin; Shanshan Zeng; Xiangzhou Chen; Min Deng; Xiaoting Jia; Yixue Gu; Danyang Chen; Guopei Zheng; Zhimin He
Journal:  Cell Death Differ       Date:  2019-07-11       Impact factor: 15.828

Review 8.  Function and mechanisms of microRNA-20a in colorectal cancer.

Authors:  Zheng Xiao; Shi Chen; Shujun Feng; Yukun Li; Juan Zou; Hui Ling; Ying Zeng; Xi Zeng
Journal:  Exp Ther Med       Date:  2020-01-08       Impact factor: 2.447

9.  MiR-10b inhibits migration and invasion of pancreatic ductal adenocarcinoma via regulating E2F7.

Authors:  Cui Xu; Xiangxiu Qi
Journal:  J Clin Lab Anal       Date:  2020-06-26       Impact factor: 2.352

10.  Trisubstituted-Imidazoles Induce Apoptosis in Human Breast Cancer Cells by Targeting the Oncogenic PI3K/Akt/mTOR Signaling Pathway.

Authors:  Chakrabhavi Dhananjaya Mohan; V Srinivasa; Shobith Rangappa; Lewis Mervin; Surender Mohan; Shardul Paricharak; Sefer Baday; Feng Li; Muthu K Shanmugam; Arunachalam Chinnathambi; M E Zayed; Sulaiman Ali Alharbi; Andreas Bender; Gautam Sethi; Kanchugarakoppal S Rangappa
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

View more
  7 in total

Review 1.  Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action.

Authors:  Mitra Behroozaghdam; Maryam Dehghani; Amirhossein Zabolian; Davood Kamali; Salar Javanshir; Farzaneh Hasani Sadi; Mehrdad Hashemi; Teimour Tabari; Mohsen Rashidi; Sepideh Mirzaei; Atefeh Zarepour; Ali Zarrabi; Danielle De Greef; Anupam Bishayee
Journal:  Cell Mol Life Sci       Date:  2022-10-04       Impact factor: 9.207

Review 2.  Emerging role of exosomes in cancer progression and tumor microenvironment remodeling.

Authors:  Mahshid Deldar Abad Paskeh; Maliheh Entezari; Sepideh Mirzaei; Amirhossein Zabolian; Hossein Saleki; Mohamad Javad Naghdi; Sina Sabet; Mohammad Amin Khoshbakht; Mehrdad Hashemi; Kiavash Hushmandi; Gautam Sethi; Ali Zarrabi; Alan Prem Kumar; Shing Cheng Tan; Marios Papadakis; Athanasios Alexiou; Md Asiful Islam; Ebrahim Mostafavi; Milad Ashrafizadeh
Journal:  J Hematol Oncol       Date:  2022-06-28       Impact factor: 23.168

Review 3.  Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies.

Authors:  Sepideh Mirzaei; Kiavash Hushmandi; Amirhossein Zabolian; Hossein Saleki; Seyed Mohammad Reza Torabi; Adnan Ranjbar; SeyedHesam SeyedSaleh; Seyed Omid Sharifzadeh; Haroon Khan; Milad Ashrafizadeh; Ali Zarrabi; Kwang-Seok Ahn
Journal:  Molecules       Date:  2021-04-19       Impact factor: 4.411

Review 4.  Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response.

Authors:  Milad Ashrafizadeh; Mahshid Deldar Abad Paskeh; Sepideh Mirzaei; Mohammad Hossein Gholami; Ali Zarrabi; Farid Hashemi; Kiavash Hushmandi; Mehrdad Hashemi; Noushin Nabavi; Francesco Crea; Jun Ren; Daniel J Klionsky; Alan Prem Kumar; Yuzhuo Wang
Journal:  J Exp Clin Cancer Res       Date:  2022-03-22

Review 5.  Molecular Mechanisms Involving the Sonic Hedgehog Pathway in Lung Cancer Therapy: Recent Advances.

Authors:  Chao Ma; Kang Hu; Irfan Ullah; Qing-Kang Zheng; Nan Zhang; Zhi-Gang Sun
Journal:  Front Oncol       Date:  2022-04-01       Impact factor: 5.738

6.  Integrated Network Pharmacology and Experimental Verification to Explore the Molecular Mechanism of Hedysarum Multijugum Maxim-Curcumae Rhizoma Herb Pair for Treating Non-Small Cell Lung Cancer.

Authors:  Shaopu Hu; Mengxue Ge; Shuixiu Zhang; Min Jiang; Kaiwen Hu; Lei Gao
Journal:  Front Oncol       Date:  2022-03-30       Impact factor: 6.244

Review 7.  Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention.

Authors:  Sepideh Mirzaei; Mahshid Deldar Abad Paskeh; Elena Okina; Mohammad Hossein Gholami; Kiavash Hushmandi; Mehrdad Hashemi; Azuma Kalu; Ali Zarrabi; Noushin Nabavi; Navid Rabiee; Esmaeel Sharifi; Hassan Karimi-Maleh; Milad Ashrafizadeh; Alan Prem Kumar; Yuzhuo Wang
Journal:  J Exp Clin Cancer Res       Date:  2022-07-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.